Work

Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer

Year: 2021

Type: article

Abstract: This comparative effectiveness research compares survival end points and response rates among patients with metastatic castration-resistant prostate cancer (mCRPC) treated with olaparib and cabazitaxel using results from 2 phase 3 randomized clinical trials.

Source: JAMA Network Open

DOI: 10.1001/jamanetworkopen.2021.10950

Authors: Christopher J. D. Wallis, Zachary Klaassen, William C. Jackson, Robert T. Dess, Zachery R. Reichert, Yilun Sun, Daniel E. Spratt

Institutions: Vanderbilt University Medical Center, Augusta University, University of Michigan, University Hospitals of Cleveland, Case Western Reserve University

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,000

OpenAlex ID: W3164096504

FWCI: 0.811

Cites: 4

Cited by: 6

Related to: 10